GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » Institutional Ownership

Gilead Sciences (LTS:0QYQ) Institutional Ownership : 66.11% (As of Apr. 24, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Gilead Sciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Gilead Sciences's institutional ownership is 66.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Gilead Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Gilead Sciences's Float Percentage Of Total Shares Outstanding is 99.93%.


Gilead Sciences Institutional Ownership Historical Data

The historical data trend for Gilead Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Institutional Ownership Chart

Gilead Sciences Historical Data

The historical data trend for Gilead Sciences can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 64.42 66.14 66.70 67.61 67.79 67.81 67.57 67.79 68.23 66.11

Gilead Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines